The panel unanimously said that the benefits of Moderna's mRNA jab outweigh its risks in preventing influenza in certain age ...

Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to ...

Moderna stays in focus as its mRNA pipeline keeps drawing attention across biotechnology and the broader healthcare space.

Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.

A Food and Drug Administration advisory panel on Thursday recommended the approval of Moderna’s mRNA-based flu shot for older ...

A federal vaccine advisory panel today gave its stamp of approval to Moderna’s mRNA influenza vaccine (mRNA-1010) for older ...

Moderna’s mRNA-centric business is in conflict with the U.S. government’s shifting views on mRNA technology, and analysts say that’s a risk. The biotech announced Tuesday evening that in a rare move, ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a ...

Hi, I'm David Berman, and I'd like to welcome you to the Moderna ASCO Oncology event. Here are forward-looking statements, and you can read them at your leisure. Here's the agenda for today. I'm going ...

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot. Reading time 3 minutes Next-generation vaccines could make the flu season ...

Moderna just received fantastic news.

The biotech company said the FDA won't review its flu vaccine, in the latest hit to mRNA development As COVID-19 vaccine sales dwindle, pressure on Moderna to grow its business has increased.